相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA
Philip Sambrook et al.
CURRENT MEDICAL RESEARCH AND OPINION (2010)
Safety of Bisphosphonates in the Treatment of Osteoporosis
Robert R. Recker et al.
AMERICAN JOURNAL OF MEDICINE (2009)
Treatment with intravenous pamidronate is a good alternative in case of gastrointestinal side effects or contraindications for oral bisphosphonates
Danielle A. Eekman et al.
BMC MUSCULOSKELETAL DISORDERS (2009)
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial
David M. Reid et al.
LANCET (2009)
Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK
J. Compston et al.
MATURITAS (2009)
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
Pierre D. Delmas et al.
BONE (2008)
Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday
J. R. Curtis et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Zoledronic acid and clinical fractures and mortality after hip fracture
Kenneth W. Lyles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Mechanisms of disease - Bone quality - The material and structural basis of bone strength and fragility
Ego Seeman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Systematic review: Bisphosphonates and osteonecrosis of the jaws
Sook-Bin Woo et al.
ANNALS OF INTERNAL MEDICINE (2006)
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study
JY Reginster et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases
JE Dunford et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients
H Dobnig et al.
OSTEOPOROSIS INTERNATIONAL (2006)
The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis
T. P. van Staa
CALCIFIED TISSUE INTERNATIONAL (2006)
Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club
JP Devogelaer et al.
OSTEOPOROSIS INTERNATIONAL (2006)
Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis
JA Cramer et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: A randomized controlled trial
G El-Hajj Fuleihan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Quality of life in patients with osteoporosis
P Lips et al.
OSTEOPOROSIS INTERNATIONAL (2005)
Severely suppressed bone turnover: A potential complication of alendronate therapy
CV Odvina et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE
CH Chesnut et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gamma delta T cells in response to aminobisphosphonates is inhibited by statins
RE Hewitt et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2005)
Ten years' experience with alendronate for osteoporosis in postmenopausal women
HG Bone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
CH Chesnut et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Seven years of treatment with risedronate in women with postmenopausal osteoporosis
DD Mellström et al.
CALCIFIED TISSUE INTERNATIONAL (2004)
The impact of compliance with osteoporosis therapy on fracture rates in actual practice
JJ Caro et al.
OSTEOPOROSIS INTERNATIONAL (2004)
Osteoporosis after solid organ and bone marrow transplantation
A Cohen et al.
OSTEOPOROSIS INTERNATIONAL (2003)
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer
MR Smith et al.
JOURNAL OF UROLOGY (2003)
Tolerability and compliance with risedronate in clinical practice
B Hamilton et al.
OSTEOPOROSIS INTERNATIONAL (2003)
Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience
OH Sorensen et al.
BONE (2003)
Meta-analysis of alendronate for the treatment of postmenopausal women
A Cranney et al.
ENDOCRINE REVIEWS (2002)
Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis
A Cranney et al.
ENDOCRINE REVIEWS (2002)
分享论文
